Human genetic studies and functional mapping highlight the incretin axis as a key regulator of metabolic health. Loss-of-function variants in GIPR are associated with lower BMI and improved cardiometabolic traits, and GLP-1 receptor antagonists are proven to deliver clinically validated benefits in metabolic diseases.
Alveus’ lead program—a GIPR antagonist/GLP-1 agonist Fusion Protein—is designed to harness the synergistic effects of these mechanisms to deliver durable, sustainable weight loss resulting in reduced treatment burden for patients.
Importantly, this dual approach aims to provide differentiated efficacy beyond current options by addressing counterregulatory metabolic mechanisms and improving long-term outcomes.
Competitive in vitro potency and weight loss with lean mass preservation in obese NHPs. Weight loss and weight maintenance demonstrated in Ph1
GIP receptor antagonism and GLP-1 receptor agonism
Novel recombinant humanized GIPR antagonist IgG-4 antibody – GLP1 agonist peptide fusion protein
Best-in-class dosing regimen
Weight Management
At Alveus Therapeutics, we are developing a portfolio of novel therapeutics targeting metabolic diseases. Despite significant improvements in treatment options and market growth; substantial unmet needs persist, particularly in achieving sustained weight loss, as well as addressing the key underlying pathologies that impact cardiometabolic health outcomes.
We aim to address these critical issues, delivering meaningful and sustained improvements in patient outcomes. In addition to our lead program, we are advancing a robust pipeline of highly differentiated small molecules, peptides, and antibodies across multiple indications.
About the Alveus Pipeline